Abaloparatide and Pelvic Fracture Healing

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 17, 2020

Primary Completion Date

April 25, 2024

Study Completion Date

April 25, 2024

Conditions
Fracture of Pelvis (Disorder)
Interventions
DRUG

Abaloparatide 80 micrograms per Pen dose

prefilled injector pen to deliver 80 micrograms daily subcutaneously

DRUG

Placebo prefilled injector pen

prefilled injector pen to deliver inactive solution daily subcutaneously

Trial Locations (3)

10021

Hospital for Special Surgery, New York

10029

Mount Sinai, New York

10595

Westchester Medical Center, Valhalla

All Listed Sponsors
collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

New York University

OTHER

collaborator

Westchester Medical Center

OTHER

lead

Hospital for Special Surgery, New York

OTHER

NCT04249232 - Abaloparatide and Pelvic Fracture Healing | Biotech Hunter | Biotech Hunter